News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Panacela Signs Contract for Approximately $4.6 Million With Russian Ministry of Industry and Trade for Development of Mobilan; Announces Appointment of Michael Fonstein as CEO and President


10/23/2013 9:30:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BUFFALO, N.Y., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that Panacela Labs, Inc., a majority-owned subsidiary of CBLI, has entered into a contract valued at approximately 149 million rubles, or approximately $4.6 million, with the Ministry of Industry and Trade of the Russian Federation for development of Mobilan, a cancer vaccine in preclinical development. Under the contract, the Russian Federation has agreed to match Panacela's funding of Mobilan over a period of approximately three years, for support of preclinical and clinical studies.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES